GSK690693 Clinical Trials

Size	Price	Qty
10mg	USD 170
50mg	USD 770

Clinical Trials

Sponsored by GlaxoSmithKline, several Phase 1 clinical trials evaluated the investigational compound GSK690693 for cancer treatment. These studies were designed to assess safety, pharmacokinetics, dosing schedules, tolerability, and preliminary anti-tumor activity. However, the recruitment status across these Phase 1 trials indicates they were ultimately terminated or withdrawn prior to completion.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00666081	WITHDRAWN	Cancer	GlaxoSmithKline	2008-04	PHASE1
NCT00493818	TERMINATED	Cancer	GlaxoSmithKline	2007-04	PHASE1
NCT00666081	Withdrawn	Cancer	GlaxoSmithKline	2008-04	Phase 1
NCT00493818	Terminated	Cancer	GlaxoSmithKline	2007-04	Phase 1

(data from https://clinicaltrials.gov, updated on 2015-04-17)

Check the GSK690693 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

GSK690693 is an ATP-competitive pan-Akt kinase inhibitor that potently suppresses Akt1, Akt2, and Akt3 isoforms, thereby blocking downstream pro-survival signaling cascades and promoting apoptosis in sensitive cell populations. By blunting Akt-dependent oncogenic signaling pathways, the compound inhibits tumor cell proliferation, providing the rationale for its clinical evaluation in Phase 1 cancer studies.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).